Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
DeCourcey DD, Steil GM, Wypij D, Agus MSD September 2013 USA | 43,107 children <19 years of age with diagnoses codes related DKA were identified and further classified as having cerebral edema if treated with mannitol and/or 3% hypertonic saline (HS) | Retrospective cohort study of patients discharged between the years 1999-2009 from 41 children’s hospitals that provided data to the Pediatric Health Information Systems databases (2B) | Use of Hyperosmolar therapies has influenced mortality rate in last decade | Overall mortality in DKA decreased by 0.25%. Use of 3% HS alone associated with higher mortality than mannitol alone in patients treated for CE. | Retrospective study using administrative database, inherent limitations and no access to the clinical records. |
Yildizdas D, Altunbasak S, Celik U, Herguner O September, 2006 Turkey | 67 Pediatric intensive care unit patients with cerebral edema of varying etiologies, including meningoencephalitis, hypoxic ischemic encephalopathy, intracranial hemorrhage, meningitis, or metabolic encephalopathy. | Group I: Received only Mannitol Group II: Received only hypertonic saline Group III: Received both mannitol and hypertonic saline. This group is subdivided into IIIA and IIIB. In Group IIIB, patients with serum osmolality greater than 325 mosmol/L had mannitol discontinued, and were treated with hypertonic saline alone. (2B) | Mortality and duration of comatose state | Mortality and duration of comatose state | Small, retrospective study. Only 7/67 patients fit into the "metabolic encephalopathy" group, which would correlate best with patients in DKA. Outcomes were "duration of comatose state" and "mortality". No mention of long-term disability. |
Szlam SM, Walsh M, Pfeffer A, Abramo, TJ October 2012 USA | 30 patients aged 3-18 years old. 2 patients were treated with HS | Descriptive retrospective analysis of electronic records from 1/2009-2/2012 for DKA patients who received 3% HS. (2C) | Effect on clinical states and GCS after administration of 3% HS. | 3% HS efficacious in improving short-term outcome without significant side effects in this population. | Retrospective study, small sample size. Larger diverse validation warranted. Only HS was used. |
Roberts MD, Slover RH, Chase HP September 2001 USA | Case reports 11 instances of severe diabetic ketoacidosis (DKA) with secondary intracerebral complications (ICCs) | Retrospective Case reports study During 1989-1999 381 episodes of DKA were treated. 9 of 11 patients were treated for DKA with CE. (3C) | Effect of prompt administration of IV mannitol on complete recovery of CE | All 9 children who received early treatment with IV mannitol showed full recovery | Retrospective study, small sample size. The other 2 of 11 patients with DKA with CE died before they could be treated. |
Morales AE, Daniels KA April 2009 USA | Case report – 15 year old girl | First published Case Report of DKA-related CE in a newly diabetes mellitus type 2. (3D) | Effect of early recognition and treatment with mannitol & 3% HS on patient’s recovery. | Full recovery of patient’s CE following treatment with mannitol & 3% HS solution. | Small sample size. Both mannitol and HS were used. |
Curtis JR, Bohn D, Daneman D December 2001 Canada | 13 year old girl with severe DKA & CE | Case report. (3D) | Complete neurological recovery | First report of successful use of HS to CE in pediatric DKA. | Both mannitol and HS were used |